Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the availability of stroke-related medicines in Northumberland; and what steps he is taking to ensure the equal provision of medicines across England.

We are aware of a supply issue affecting aspirin 300 milligram suppositories until late June 2025, which are used outside of their license of pain and inflammation, for their antiplatelet effect after a stroke. We have issued shortage management guidance to the National Health Service advising on the alternative, aspirin 150 milligram suppositories, which remain available for affected patients.

The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information on stock levels within Northumberland is not held centrally.

Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues. We have drawn on up-to-date intelligence and data on the root causes of medicine supply issues, with manufacturing problems being the most dominant root cause. The Department works closely with industry, the NHS, manufacturers, and other partners across the supply chain to make sure patients across the UK can access the medicines they need.

The resilience of UK supply chains is a key priority, and we are continually learning and seeking to improve the way we work to both manage and help prevent supply issues and avoid shortages. The Department, working closely with NHS England, is taking forward a range of actions to improve our ability to mitigate and manage shortages and to strengthen our resilience. As part of that work, we continue to engage with industry, the Medicines and Healthcare products Regulatory Agency, and other colleagues across the supply chain as we progress work to co-design and deliver solutions. We have plans underway to increase the awareness of our work.